IDENTIFICATION OF A NOVEL HUMAN RECEPTOR TYROSINE KINASE GENE

Abstract: A DNA sequence encoding a novel human growth factor receptor referred to as a type III receptor tyrosine kinase is described. The amino acid sequence of the receptor is also described. The receptor has a sequence which is similar to that of the kinase domains of known type III receptor tyrosine kinases, but which is unique in its kinase insert domain sequence. The receptor binds specifically to the vascular endothelial cell growth factor.

Description: IDENTIFICATION OF A NOVEL HUMAN RECEPTOR TYROSINE KINASE GENE FIELD OF THE INVENTION This invention relates to the DNA sequence encoding a novel human growth factor receptor which is a type III receptor tyrosine kinase. The receptor is referred to as Kinase insert Domain containing Receptor (KDR) and binds specifically to the growth factor vascular endothelial cell growth factor (VEGF) . This invention also relates to the amino acid sequence of the receptor. BACKGROUND OF THE INVENTION Growth factors are small molecules which regulate normal cell growth and development through interaction with cell surface receptors. The receptors for a number of growth factors are referred to as tyrosine kinases; that is, binding of growth factor to the receptor stimulates an increased phosphorylation of tyrosine amino acids within the receptor; this is turn leads to cellular activation (Bibliography 1) . There is increasing evidence that genetic alterations affecting the expression of receptor tyrosine kinases (RTK) can contribute to the altered cell growth associated with cancer. This conclusion is - 2 - supported by the frequent identification of RTK as products of the oncogenes for many of the acutely transforming retroviruses (e.g., 2,3,4) and the overexpression of RTK in certain cancers (5) . The identification of a novel RTK may lead to a better understanding of cell growth under both normal and transforming circumstances. The amino acid sequence in the catalytic domain of all tyrosine kinases has been conserved (6) . Detailed analysis of the amino acid sequences within the catalytic and noncatalytic domains of RTK indicates the existence of distinct structural subtypes. One group of RTK (designated type III) includes the ckit proto-onσogene and the receptors for platelet derived growth factor (PDGF) and colony stimulating factor-1 (CSF-1) . The most unusual feature of this subtype is that its catalytic (kinase) domain is interrupted by a long insertion sequence of 12-102 amino acids (the kinase insert domain) The two peptides constituting the kinase domain are conserved between the receptors, while the sequence of the kinase insert domain is unique for each receptor. Several approaches have been tried in order to identify novel RTK, including low-stringency screening of cDNA libraries with previously characterized DNA probes (7) . More recently, a technique has been developed that is capable of greatly facilitating the identification of novel genes for which some sequence data are known. The polymerase chain reaction (PCR) has been used to identify novel members of several gene families including those of guanine nucleotide regulatory proteins (8) and protein phosphatases (9) . PCR has been used to identify novel tyrosine kinase genes (10) , though the primers used in - 3 - that study were designed from DNA segments contained in all tyrosine kinases, rather than being specifically directed against RTK. It is a continuing goal to identify receptors for growth factors. The elucidation of the growth factors, as well as their receptors, involved in regulating endothelial cell function is critical for the understanding of how new blood vessels are formed (angiogenesis) . Angiogenesis plays a significant role in both normal and pathological events such as embryogenesis, progression of ocular diseases, and wound healing (11) . In particular, angiogenesis is an important process for the growth of tumors (11) . Angiogenesis is a complex process involving endothelial cell proliferation, migration, and tissue infiltration. These events are stimulated by growth factors which either (i) act directly on endothelial cells (12,13), or (ii) act indirectly by inducing host cells to release specific endothelial cell growth factors (11) . one member of the first group is vascular endothelial cell growth factor (VEGF) , also known as vascular permeability factor (14-16) . Besides its angiogenic activity, VEGF displays the physiological function of increasing the permeability of capillary vessels to different macromolecules (14) . SUMMARY OF THE INVENTION The present invention relates to novel DNA segments which together comrpise a gene which encodes type III RTK. The type III RTK encoded by the gene is designated the KDR protein (which stands for Kinase insert Domain containing Receptor) . The KDR protein binds specifically to the growth factor VEGF (vascular endothelial cell growth factor) . - 4 - The DNA segments are identified and isolated through the use of PCR technology. The overall strategy is summarized as follows: PCR is used to amplify the DNA segments corresponding to the kinase insert domains of type III receptor tyrosine kinase genes in an endothelial cell library designated HL10246 (Clontech Laboratories, Inc., Palo Alto, CA) . Degenerate oligonucleotide primers are designed which are complementary to conserved tyrosine kinase domains flanking the kinase insert domains of known type III receptor tyrosine kinases. These primers are used in the PCR procedure. DNA probes, designed from the DNA sequence of the PCR product, are then used to identify cDNA clones of the receptor gene from the original cDNA library. In particular, the present invention relates to specific oligonucleotides which, when used as primers for PCR, allow for the amplification of DNA segments corresponding to the kinase insert domains of type III RTK genes. In a principal embodiment, the present invention is directed to three overlapping DNA segments (designated BTIII081.8, BTIII129.5 and BTIV169) which comprise the entire coding region of this novel gene, namely, 4,068 nucleotides extending to the 3' end. These DNA segments are isolated from a human endothelial cell cDNA library and together comprise the gene coding for a novel type III receptor tyrosine kinase. The human gene containing these DNA segments is referred to hereinafter as KDR (which stands for Kinase insert Domain containing Receptor) or, alternatively, as kdp (which stands for Kinase insert Domain containing Protein) . The use of the term KDR is intended to include any DNA segments which form the - 5 - human gene which encodes the novel type III RTK of this application. The DNA segments embodied in this invention are isolated from human sources. The present invention comprises DNA segments, and methods for using these DNA segments, which allow for the identification of a closely related gene in mouse DNA. The methods developed in this invention can be readily used by those skilled in the art for the identification and isolation of closely-related homologues in other species. Therefore, the present invention also embodies all DNA segments from species other than human which encode proteins having substantially the same amino acid sequence as that encoded by the kdp gene. The present invention further relates to methods developed for the detection of mRNA's produced as a result of transcription of the sense strands of the DNA segments of this invention. Messenger RNA prepared from bovine endothelial cells are used in developing these methods. The ability to detect mRNA for a novel RTK may ultimately have medical benefit, especially in light of recent observations that the mRNA for certain RTKs are overexpressed in some cancers (5). The methods developed in the present invention for detecting mRNA expressed by the kdp gene can be readily used by those of ordinary skill in the art for the detection of mRNA species related to the kdp gene in any cell type and from any species. For this reason, the present invention embodies all mRNA segments which are the result of transcription of the kdp gene. The present invention relates to methods for expression of the receptor protein, for example, in CMT-3 cells of monkey kidney origin. The receptor PCr. US92.01M0 - 6 - protein, portions thereof, and mutated forms of the receptor protein may be expressed in many other cells by those skilled in the art using methods similar to those described in this application. For this reason, 5 the present invention embodies all proteins encoded by the human KDR gene and proteins encoded by related genes found in other species. The present invention further relates to methods for studying the interaction of VEGF to the 10 expressed KDR protein. Recent work in the literature (17) indicates that VEGF is one member of a family of related proteins, and the interaction of growth factors similar to VEGF with the KDR protein can readily be studied by those skilled in the art using methods 15 similar to those described in this application. These methods can readily be modified to study the interaction of candidate pharmaceuticals with the KDR protein towards the goal of developing an antagonist or agonist of VEGF action. For this reason, the present 20 invention embodies methods for studying the interaction of VEGF and VEGF-related growth factors with the KDR protein. BRIEF DESCRIPTION OF THE DRAWINGS 25 Figure 1 depicts a schematic representation of three receptor tyrosine kinase subclasses (6) . KI is kinase insert domain; PTK is kinase domain; cys is cysteine rich region. 30 Figure 2 depicts the two sets of primers used for PCR (SEQ ID No: 1 and 2) . The nucleotide sequences in appropriate regions of the four known type III receptor tyrosine kinase cDNAs are aligned and degenerate oligonucleotide primers are designed based 35 upon the consensus sequences. - 7 - Figure 3 depicts the amplification of the kinase insert domains using PCR. DNA segments encoding the kinase insert domains of type III receptor tyrosine kinases are amplified by PCR. A sample (5 μl) is run on a 1.0% agarose gel which is stained with ethidium bromide. DNA size standards (123 bp ladder; Bethesda Research Laboratories, Bethesda, MD) are run as well. Figure 4 depicts the DNA sequence of the two PCR products (Panel A: 363 bp segment derived from the 420 bp product (SEQ ID NO: 3) ; Panel B: 251 bp product (SEQ ID NO: 4)). The two products are purified by agarose gel electrophoresis, digested with Sail and EcoRI. and cloned into the plasmid vector pBlueScribe(+) (Strategene; San Diego, CA) . The 420 bp PCR product is digested to 363 bp during this procedure. The DNA sequences for the primers used in the amplification are underlined. Figure 5A depicts a computer assisted comparison of the DNA sequence for the 363 bp DNA segment derived from the 420 bp PCR product with the sequence of a DNA segment of the PDGF receptor (SEQ ID NO: 5) (18) . A region of strong homology between the 363 bp segment derived from the 420 bp PCR product and the PDGF receptor is contained in a box. Figure 5B depicts a computer assisted comparison of the DNA sequence for the 251 bp PCR product with the sequence of a DNA segment of the FGF receptor (SEQ ID NO: 6) (7). Figure 6 depicts the strategy used for sequencing the insert portions of clones BTIII081.8 and BTIII129.5 and BTIV169. The sequencing reaction uses either synthetic oligonucleotides (represented by boxes at the start of an arrow) , or the M13 universal primer (no box) to initiate the reaction. In some cases, portions of these DNA segments are isolated using the restriction enzymes indicated in the figure, and subcloned back into the plasmid vector pUCllδ, so that the M13 universal primer can be used. The position of the stop codon in BTIII129.5 is indicated. The coding portions of these DNA segments are shown at the bottom of the figure. The relative positions of the 1) membrane spanning portion, 2) kinase domains, and 3) kinase insert domain are indicated. The position of these structural features within the KDR derived DNA segments is compared in relation to their position in the PDGF-receptor ("PDGF-R") . Figure 7 depicts the DNA and predicted amino acid sequence of KDR. plus the stop codon (nucleotides 1-4071 of SEQ ID NO. 7) . The sequence of the DNA segment amplified by PCR is underlined (nucleotides 2749-3105 of SEQ ID NO. 7) . Cysteine residues in the putative extracellular domain are circled. Potential N-linked glycosylation sites are indicated by an asterisk. The putative membrane spanning region is enclosed in a box (nucleotides 2293-2367 of SEQ ID NO. 7). Figure 8 depicts a hydropathy plot of the predicted amino acid sequence for the KDR protein. Figure 9 depicts a comparison of the predicted amino acid sequence in the putative intracellular portion of the KDR protein to the ckit proto-oncogene (SEQ ID No: 8) (3) , the CSF-1 receptor (SEQ ID NO: 9) (4) , and the PDGF receptor (SEQ ID NO: 10) (18) . Exact matches are indicated by an asterisk. Gaps are introduced to achieve maximum alignment. The putative ATP recognition site is indicated by three asterisks. Figure 10 depicts the identification of kdp receptor mRNA by Northern blot analysis. Five micrograms of bovine aortic endothelial cell polyA+ RNA . - 9 - are used. A nick-translated [ 32P] CTP-labelled EcoRI/BamHI DNA segment (nucleotides 1510-2417 of SEQ ID NO. 7) is used as a probe. Autoradiography is for 36 hours. Figure 11 depicts the kdp gene in human and mouse DNA by Southern blot analysis. A nick translated [ 32P]CTP-labelled EcoRI/BamHI DNA segment (nucleotides 1510-2417 of SEQ ID NO. 7) is used as the probe. The probe is hybridized to Southern blots containing EcoRI digested DNA from human (lane 1), mouse (lane 2), and human-mouse hybrid cells (19) (lanes 3 and 4) . The DNA used in lane 3 lacks the kdp locus, while DNA used in lane 4 contains the kdp locus. Figure 12 depicts a Western blot analysis of CMT-3 cells which express the KDR protein. Cells are transfected with either the pσDNAltkpASP vector alone (lane 1) or with that vector modified to contain the KDR gene (lane 2) . 2 x 10 cells and 1 microgram of DNA are used for each transfection. Forty-eight hours later. Western blot analysis is performed on the samples using the anti-KDR.PS23 polyclonal antibody at a dilution of 1:1000. Detection of reacting proteins is performed using an ECL system (Amersham, Chicago, IL) . Figure 13 depicts the results of [ 125I] VEGF binding to CMT-3 cells which express the KDR protein. Cells are transfected with either the vector alone (bars 1 and 2) or with the vector containing the KDR gene (bars 3 and 4) . Forty-eight hours later, the samples are washed with phosphate buffered saline (PBS) , and incubated with serum-free media containing 50 pM [ 125I] VEGF (specific activity equal to 4,000 cpm per fmol) , for 90 minutes. Nonradioactive VEGF, 5 nM, is added to some samples (bars 2 and 4) to define specific binding sites. The samples are washed with ice cold PBS, and the cells are transferred to gamma-counting tubes using 0.1% lubrol. Figure 14 depicts the results of affinity cross-linking of [ I] VEGF to CMT-3 cells which express the KDR protein. CMT-3 cells are transfected with either the vector alone (lane 1) or with the vector containing the KDR gene (lane 2) . Forty-eight hours later, the cells are washed in PBS, and serum free media containing 200 pM [ 125 I] VEGF is added. After 90 minutes at room termperature, an affinity cross-linker disuccinimidyl suberate, 0.5 mM, is added for 15 minutes. The samples are then prepared for SDS-PAGE autoradiography. DETAILED DESCRIPTION OF THE INVENTION The strategy used to discover the DNA segments for the novel type III RTK gene begins with the design of two degenerate oligonucleotide primers based upon their homology to specific regions of the kinase domains of known RTK genes (Fig. 2) (3,4,7,18). In one embodiment, the polymerase chain reaction is then used to amplify DNA segments from a human endothelial cell cDNA library (designated HL 10246) . The cDNA products from this step are each cloned into a plasmid vector designated pBlueSσribe+ (Strategene, San Diego, CA) and sequenced. Oligonucleotide probes are designed from potentially interesting sequences in order to screen the cDNA library for more full length clones of the novel cDNA. The strategy just described provides several novel elements: 1) the DNA sequences of the oligonuc¬ leotide primers used during PCR; 2) the DNA sequence of the products generated by the polymerase chain reaction; and 3) the DNA sequence of the final cloned DNA segments. Each of these elements of the invention described in this application will now be discussed in detail. Figure 2 shows the rationale for choosing the oligonucleotide primers used in the PCR. The primers are designed to allow for the PCR amplification of the kinase insert domain of type III RTK genes. In order to design the primers, the DNA sequences of known type III RTK genes are aligned in specific regions of their catalytic domains, and a consensus sequence is chosen. The regions of the catalytic domains chosen in designing the primers flank the kinase insert domains of the receptor genes. Primer 1 (SEQ ID No: 1) is designed from a region of the kinase domain 5 1 to the kinase insert domain, and consists of a mixture of four different 21mers. Primer 2 (SEQ ID NO: 2) is designed from a region of the kinase domain 3' to the kinase insert domain, and consists of a mixture of sixteen different 29mers with one inosine, indicated in SEQ ID NO: 2 by "N". Sail and EcoRI restriction sites are included at the 5' end of primers 1 and 2, respectively, to facilitate the subcloning of the amplified PCR products into plasmid vectors. Those skilled in the art may use other restriction sites; other minor modifications in the protocol above permits the design of primers without the inclusion of restriction sites. The selection of these specific primers constitutes a novel approach towards identifying novel type III RTK genes. It had previously been shown (10) that primers designed from DNA sequences common to all tyrosine kinases allows for the identification of novel proteins. The present invention is the first to contemplate the use of PCR to specifically target type III RTK. The protocol used for PCR is as follows: Human endothelial cell cDNA (designated HL10246) is denatured by boiling and submitted to 30 cycles of PCR using 1 nmol of both primers in a final volume of 100 μl. The timing is 1.5 minutes at 92 C, 2 minutes at 50°C, and 2 minutes at 74°C. DNA from 5μl of sample is separated on a 1% agarose gel and stained with ethidium bromide. Figure 3 shows the results of the PCR amplification. Two DNA products, with sizes 251 bp (SEQ ID NO: 4) and 420 bp, are visible when a sample of the reaction is electrophoresed on a 1.0% agarose gel and stained with ethidium bromide. The sizes of the two products are within the range expected for type III RTK genes (products derived from the FGF and PDGF receptor genes, which have the smallest and largest known kinase insert domains, would be 230 and 510 bp, respectively (20, 21). The DNA from four continguous lanes with sizes ranging from 200 to 600 bp is electrophoresed onto DEAE filter paper, eluted from the paper with salt, and ethanol precipitated. The samples are incubated with 5 units of EcoRI and Sail. The restriction enzymes digest the 420 bp DNA segment to a 363 bp DNA segment (SEQ ID NO: 3) , due to the presence of an EcoRI site within the 420 bp DNA segment (nucleotide 2749, SEQ ID NO. 7). The restriction enzyme digested PCR products are then subcloned into the plasmid vector pBlueScribe(+) . The recombinant clones are analyzed by sequencing using the dideoxy-method (22) using a United States Biochemical (Cleveland, Ohio) Sequenase Version 2.0 sequencing kit. Figure 4 shows the DNA sequences for the 251 bp PCR product and the 363 bp DNA segment derived from the 420 bp PCR product. Computer assisted comparison of the DNA sequence for the 363 bp segment of the 420 bp PCR product to databases of known DNA sequences reveals that the sequence is novel, because it shares strong sequence identity with the flanking catalytic domain of known type III RTK genes, but not their kinase insert domains. Figure 5A compares the DNA sequence for the 363 DNA segment with that for the PDGF receptor gene (SEQ ID No: 5) . Similar results are obtained using other type III RTK genes. DNA sequencing of the 251 bp PCR product reveals a novel sequence containing both primers used for the amplification, but the sequence shows little homology to known tyrosine kinases. This is depicted in Figure 5B, which compares the DNA sequence for the 251 bp DNA segment with that for the FGF receptor (SEQ ID NO: 6) . For this reason, further analysis of Product 1 is not pursued. The protocols used during the PCR do not allow for amplification of the kinase insert domains of known receptor tyrosine kinases in the endothelial cell library used because of the low copy number of the message present in the library. There have been many studies on the effect of FGF on endothelial cell function (23,24) although there is evidence that the expression of the FGF receptor is developmentally regulated (7) and it is likely that the library used contains little or no cDNA for the FGF receptor. An oligonucleotide probe, designed from the DNA sequence of the 363 bp segment, is synthesized (using an ABI 380 DNA Synthesizer) in order to screen the human endothelial cell cDNA library (HL10246) for the isolation of more full length clones containing the 01300 - 14 - 363 bp DNA segment. The probe sequence is chosen from the region of the 363 bp DNA segment which shares little sequence homology with known RTK. The screening of the endothelial cell cDNA library is conducted as follows: Lambda gtll phage, 10 , are adsorbed to E. coli .LE392 for 15 minutes at 37°C prior to plating onto agar plates at a density of 5 x 10 phage per plate. After allowing the phage plaques to develop at 37°C, plaque lifts are made using nitrocellulose filters, denatured in 0.4 N NaCl for 1 minute, and neutralized in 0.5 M Tris.HCl, pH 7.3, plus 1.5 M NaCl. The filters are washed with 2 x standard saline citrate (SSC) and then baked for 1.5 hour in a vacuum oven at 80°C. The filters are probed with an [ 32P] ATP end labeled synthetic oligonucleotide, 5' - TTTCCCTTGACGGAATCGTGCCCCTTTGGT-3', which is the reverse complement of a DNA sequence contained in the PCR amplified product (Fig. 3) . Hybridization is performed at 50°C in 5 x SSPE (167 mM NaCl, 10 mM sodium phosphate, pH 7.4, 1 mM EDTA) , 2.5 x Denhardts, 0.5% sodium dodecyl sulfate (SDS) , 100 μg/ml salmon sperm DNA. The filters are washed twice, 20 minutes per wash, with 2 x SSC plus 0.1% SDS at room temperature, followed by washing twice at 50°C with 0.1 X SSC plus 0.1% SDS; 20 minutes per wash. Positive clones are identified, picked and plaque purified. Forty-five positive clones are obtained. Three of these positive clones are plaque purified and their phage DNA isolated. Digestion of the DNA with EcoRI and electrophoresis in agarose indicates that one clone, designated BTIII081.8, contains the largest insert, and subsequent analysis indicates that the DNA insert of this clone overlaps that of the inserts contained in other two purified clones (designated BTIII079.il and BTIII079.47A) . Digestion of the purified phage DNA of the clone designated BTIII081.8 with EcoRI results in DNA segments of 250 bp, 600 bp, and 1000 bp. Each of these three products is subcloned into the plasmid vector pUCllδ and sequenced (Figure 6 shows the strategy used for sequencing) . The orientation of the three fragments is determined by subcloning from the insert a Bglll/Bglll fragment into pUCllδ and sequencing across the EcoRI junctions using a synthetic oligonucleotide to prime the sequencing reaction. A restriction map is determined for each fragment (Figure 6) . Various restriction site pieces are removed from the plasmids and recloned into pUC118 so that sequencing the resulting plasmids with the universal primer allows for sequencing most of the entire original fragments in both directions. Three oligonucleotide primers are required to sequence the entire cDNA in both directions. For the purposes of this application, this insert contains nucleotides numbered 1510-3406 (SEQ ID NO. 7) . A [ 32P]CTP-labelled, ni.ck-translated EcoRI-BamHI DNA segment derived from clone BTIII081.8 (nucleotides 1510-2417 of SEQ ID NO. 7) is used as a probe to rescreen the original endothelial cell cDNA library for more 5 1 full length DNA segments of the gene from which the insert portion of BTIII081.8 is derived. The protocols used to isolate the overlapping clones are identical to that used to isolate BTIII081.8. A synthetic oligonucleotide probe is designed with 29 nucleotides corresponding to part of the DNA sequence of the insert portion of the clone BTIII081.8 (nucleotides 3297-3325 of SEQ ID NO. 7) in order to rescreen the original endothelial cell cDNA library for more full 3' length DNA segments of the gene from which the insert portion of BTIII081.8 is derived. The protocols used to isolate the overlapping clones are identical to that used to isolate BTIII081.8. Several positive clones for each of the 5 1 and 3' ends are identified and plaque purified. One of the clones is designated BTIII200.2. The DNA from BTIII200.2 contains a 3.4 kb insert as determined by EcoRI digestion of the isolated phage DNA. EcoRI digestion of BTIII200.2 results in three DNA fragments. One of thse fragments (2.5.kb) is cloned into pUC119 and is designated BTIV006. The clone BTIV006 contains nucleotides numbered 7-2482. As described below, BTIV006 plus nucleotides 1-6 is designated BTIV169. DNA sequencing of the 2.5 kb DNA insert (BTIV169) indicates that it overlaps over one thousand nucleotides of the DNA sequence of the insert portion of the clone BTIII081.8 (Figure 6) at the 5' end. A second clone isolated from the cDNA library is designated BTIII129.5. The DNA from BTIII129.5 contains a 2.2 kb insert as determined by EcoRI digestion of the isolated phage DNA. DNA sequencing of the 2.2 kb DNA insert indicates that it overlaps over five hundred nucleotides of the DNA sequence of the insert portion of the clone BTIII081.8 (Figure 6). The clone BTIII129.5 contains nucleotides numbered 2848-4236 (SEQ ID NO. 7) . The DNA sequence for BTIII129.5 contains the stop codon TAA, defining the position of the 3• end of an open reading frame for the novel gene. Except for the first six nucleotides of the gene which are discussed below, these three clones define a gene encoding a growth factor receptor. These three clones define a 4,062 nucleotide sequence of the open reading frame of the gene extending to the 3 ' end, followed by a 168 nucleotide non-coding region (SEQ ID NO. 7) . A sample of a lambda gtll phage harboring the clone BTIII081.8 has been deposited with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20852, U.S.A., and has been assigned ATCC accession number 40,931. A sample of a lambda gtll phage harboring the clone BTIII129.5 has been deposited with the American Type Culture Collection and has been assigned ATCC accession number 40,975. For reasons discussed below, a sample of the clone BTIV006 was not deposited. The aforementioned DNA segments (BTIII081.8, BTIII129.5, and BTIII200.2 (or BTIV006) encode 4062 nucleotides of the coding portion of a novel gene. The cDNA clones are incomplete in that a transcription initiation coding for methionine is missing. After the isolation of these clones, Matthews et al. (25) reported the cloning of a gene homologue of KDR in mouse, which was referred to as Flk-1. Analysis of the nucleic acid and amino acid sequence of Flk-1 indicated that the addition of six nucleotides to the 5' end of the isolated KDR clones would provide for a complete coding region. To achieve this, an EcoRI-BamHI restriction fragment of BTIV200.2 is cloned into the plasmid pBlueScript KS (Strategene, La Jolla, CA) . The 5 1 end of the inserted DNA is blunt ended with Klenow polymerase and Mung Bean nuclease. Next, the synthetic oligonucleotide TCGACGCGCG ATG GAG (SEQ ID NO. 11) is cloned into this vector. The oligonucleotide contains the sequence ATG GAG in frame with the downstream DNA insert. These nucleotides (ATG GAG) encode the amino acids methionine and glutamic acid, the first two amino acids encoded by the KDR gene. The resulting plasmid vector is designated BTIV140. This plasmid is purified on a CsCl gradient. The purified plasmid is designated BTIV169. The insert of BTIV169 contains nucleotides 1-2400 (SEQ ID NO. 7) of the KDR gene. A sample of the plasmid pBlueScript KS which contains the clone BTIV169 has 5 been deposited with the .American Type Culture Collection and has been assigned ATCC accession number 75200. Thus, together the clones BTIII081.8, BTIII129.5 and BTIV169 comprise the entire open reading 10 frame of 4,068 nucleotides for the novel KDR gene. As will be discussed below, the KDR gene expresses the novel KDR receptor which binds specifically to the growth factor VEGF. DNA sequencing of BTIII081.8, BTIII129.5 and 15 BTIV169 (SEQ ID NO. 7) shows that the newly isolated gene is similar to, but distinct from, previously identified type III RTK. The predicted amino acid sequence (SEQ ID NO. 7) contains several structural features which demonstrate that the novel gene is a 20 type III RTK. These structural features are summarized as follows: 1) A hydropathy plot of the predicted amino acid sequence indicates a single membrane spanning region (see Figure 8) . This is characteristic of a 25 type III RTK (Figure 7) . 2) The putative amino-terminal 762 amino acid portion of the receptor has structural features of extracellular receptor ligand binding domains (1) , including regularly spaced cysteines and 18 potential 30 N-linked glycosylation sites (Figure 7) . 3) The predicted amino acid sequence of the carboxy-terminal 530 amino acid portion contains an ATP-binding site at lysine 868, 22 amino acids downstream from the consensus ATP recognition sequence 35 Gly-X-Gly-X-X-Gly (26) (Figure 8) . 4) Within the kinase domain there is a 55-60% identical match in amino acid sequence to three other type III receptor tyrosine kinases: ckit proto-oncogene (SEQ ID NO: 8) , CSF-1 (SEQ ID NO: 9) and PDGF (SEQ ID NO: 10) (Figure 9) . 5) The predicted kinase domain contains a kinase insert domain of approximately 71 amino acids. As indicated in Figure 9, this portion of the amino acid sequence shares little sequence homology with other type III RTK. The endothelial cell library can be further screened to isolate the 5' untranslated region and genomic clones can be generated so as to isolate the promoter region for the KDR gene. In addition to the DNA sequence described for the KDR gene (SEQ ID NO. 7) , the present invention further comprises DNA sequences which, by virtue of the redundancy of the genetic code, are biologically equivalent to the sequences which encode for the receptor, that is, these other DNA sequences are characterized by nucleotide sequences which differ from those set forth herein, but which encode a receptor having the same amino acid sequences as those encoded by the DNA sequences set forth herein. In particular, the invention contemplates those DNA sequences which are sufficiently dupliσative of the sequence of SEQ ID NO. 7 so as to permit hybridization therewith under standard high stringency Southern hybridization conditions, such as those described in Sambrook et al. (27), as well as the biologically active proteins produced thereby. This invention also comprises DNA sequences which encode amino acid sequences which differ from those of the novel receptor, but which are the biological equivalent to those described for the receptor. Such amino acid sequences may be said to be biologically equivalent to those of the receptor if their sequences differ only by minor deletions from or conservative substitutions to the receptor sequence, such that the tertiary configurations of the sequences are essentially unchanged from those of the receptor. For example, a codon for the amino acid alanine, a hydrophobic amino acid, may be substituted by a codon encoding another less hydrophobic residue, such as glycine, or a more hydrophobic residue, such as valine, leucine, or isoleucine. Similarly, changes which result in substitution of one negatively charged residue for another, such as aspartic acid for glutamic acid, or one positively charged residue for another, such as lysine for arginine, as well as changes based on similarities of residues in their hydropathic index, can also be expected to produce a biologically equivalent product. Nucleotide changes which result in alteration of the N-terminal or C-terminal portions of the protein molecule would also not be expected to alter the activity of the protein. It may also be desirable to eliminate one or more of the cysteineε present in the sequence, as the presence of cysteines may result in the undesirable formation of multimers when the protein is produced reσombinantly, thereby complicating the purification and crystallization processes. Each of the proposed modifications is well within the routine skill in the art, as is determi¬ nation of retention of biological activity of the encoded products. Therefore, where the terms "KDR gene" or "KDR protein" are used in either the specification or the claims, each will be understood to encompass all such modifications and variations which result in the production of a biologically equivalent protein. In addition to the full length gene and protein, the invention encompasses biologically active fragments of each. By "biologically active" is meant a protein fragment which qualitatively retains the receptor activity of the larger KDR protein, or, in the case of a nucleotide sequence, which encodes such a protein fragment. It also refers, for purposes of antibody production, to fragments which are capable of eliciting production of antibodies capable of binding to the receptor protein. To determine the size of the mRNA transcribed from the kdp gene. Northern blot hybridization experiments are carried out using an EcoRI/BamHI DNA segment (nucleotides 1510-2417, SEQ ID NO. 7) as a hybridization probe. The DNA used for the probe does not contain any portion of the putative kinase domain, and shares little sequence homology to other tyrosine kinases. The Northern blot analysis (Figure 10) shows that a 7 kb band is visualized in cytoplasmic poly(A)+ RNA of ABAE bovine aortic endothelial cells. This transcript differs in size from previously reported transcripts for known type III RTK (7,18). The isolated cDNA is significant for several reasons. The cDNA encodes a novel type III receptor tyrosine kinase. The homology between the sequence of this cDNA and that of other receptors, as well as structural properties implied by the predicted amino acid sequence confirm the relationship. Receptors for growth factors should have tremendous utility in drug development as they face the outside of the cell and thus are among the best targets for drugs. In addition, the cellular levels of some receptors, in particular the neu proto-oncogene, increase during some cancers. This has been taken advantage of in designing diagnostic tests for these cancers. Southern analysis demonstrates that the kdp gene is present in mouse as well as human DNA. Mouse and human (Hela cell) DNA, 15 μg of each, are digested with 10 units of EcoRI and electrophoresed on a 0.7% agarose gel. The DNA is transferred onto nitrocellulose. The filter is hybridized to a [ 32P]CTP-labelled cDNA probe made by nick translating an EcoRI/BamHI fragment from the 5' end of the kdp cDNA (nucleotides 1510-2417, SEQ ID NO. 7). Hybridization is conducted at 30°C in 5 X SSPE, 50% formamide, 0.1% SDS, plus 150 μg/ml salmon sperm DNA. The DNA probe hybridizes to Southern blots containing EcoRI digested DNA. After 48 hours, the filter is washed at room temperature in 2 X SSC plus 0.1% SDS for 20 minutes, followed by two 20 minute washes at 40°C with 0.1 X SSC plus 0.1% SDS. Autoradiography is then performed for 48 hours. As shown in Figure 11, radioactively labelled DNA is present in both human and mouse samples. This indicates that the kdp gene is present in both species. An experiment is conducted to ascertain the genetic locus of kdp on human chromosomes. Thirty-eight cell hybrids from 18 unrelated human cell lines and four mouse cell lines are examined (19) . A DNA probe hybridizes to Southern blots which contain EcoRI digested DNA from the human-mouse hybrids (using the procedure and DNA probe for human and mouse tissue described in relation to Figure 11) . Table I sets forth the results of the segregation of kdp with human chromosomes in EcoRI digested human-mouse somatic cell hybrid DNA: Table I Concordant # Discordant # of Hybrids of Hybrids The scoring is determined by the presence(+) or absence (-) of human bands in the hybrids on Southern blots prepared in a similar to those shown in Figure 11. The scoring is compared to the presence or absence of human chromosomes in each hybrid. A 0% discordancy indicates a matched segregation of the DNA probe with a chromosome. Three fragments, approxi¬ mately 6.5 kb, 3.1 kb, and 0.7 kb in size are detected in digests of human DNA (Figure 11) , and in all hybrids which had retained human chromosome 4 (Table I) . All other chromosomes are excluded in at least 11 discordant hybrids (Table I) . The results of Figure 11 and Table I demonstrate that the genetic locus of kdp is on human chromosome 4. It is noteworthy that both the ckit (3) and the type A PDGF (28) receptor genes map to human chromosome 4. The finding that the genetic locus of kdp is on human chromosome 4 provides further evidence that the novel receptor of this invention is a type III receptor tyrosine kinase. The next step after identifying the entire coding portion of the kdp gene is to express the receptor protein encoded by that gene. The receptor protein is then utilized so as to identify the growth factor which binds specifically to the receptor. The receptor protein is expressed using established recombinant DNA methods. Suitable host organisms include bacteria, viruses, yeast, insect or mammalian cell lines, as well as other conventional organisms. For example, CMT-3 monkey kidney cells are tranfected with a vector containing the complete coding region of the KDR gene. The complete coding portion of the KDR gene is assembled by sequentially cloning into pUC119 three DNA fragments derived from BTIII081.8, BTIII129.5, and BTIV169. First, a Smal-EcoRI fragment of clone BTIII129.5 (nucleotides 3152-4236, SEQ ID NO. 7) is blunt ended with Klenow polymerase and introduced into a Smal site in pUC119. Next, a BamHI-Smal fragment of clone BTIII081.8 (nucleotides 2418-3151, SEQ ID NO. 7) is introduced at a BamHI-S al site. Finally, a Sall-BamHI fragment of clone BTIV169 (nucleotides 1-2417, SEQ ID NO. 7) is introduced at a Sall-BamHI site. Part of the cloning site of pUC119 is contained in the Sall-BamHI fragment, 5 1 to the KDR gene. In order to clone the complete coding portion into an expression vector, the assembled DNA (in pUC119) is digested with Sail and Aspll8 and recloned into the eukaryotic expression vector pcDNAltkpASP. This vector is a modification of the vector pcDNAl (Invitrogen; San Diego, CA) . Specifically, the ampicillin resistance gene is cloned from pBR322 into pcDNAl. A small SV40 T splice and the SV40 polyadeny- lation signal are then removed and are replaced with a Herpes Simplex Virus-1 polyadenylation signal. Finally, a cyto egalovirus intermediate early splice is inserted 5' to the cloning site to yield pcDNAltkpASP. Transfeσtion of CMT-3 cells is done using DEAE-dextran. Forty-eight hours after transfeσtion, expression of the novel receptor is monitored using Western blot analysis as follows. An antibody is used to assay the expressed receptor protein. The predicted amino acid sequence of the receptor is used to generate peptide-derived antibodies to the receptor by conventional techniques. The presence of the novel receptor protein is confirmed by Western blot hybridization. Specifically, a synthetic peptide with 13 residues is synthesized based on the 12 residues corresponding to amino acids 986-997 of the putative amino acid sequence of the KDR protein (SEQ ID NO. 7) , with a cysteine residue linked to the lysine (amino acid 997) . The cysteine facilitates coupling of the peptide to a macromolecule which functions as a carrier for the peptide. For example, the peptide is coupled 1 00 - 26 - to keyhole limpet haemocyanin (KLH) using m-maleimido- benzoyl-N-hydroxysuccinimide ester. Other conventional carriers may be used such as human and bovine serum albumins, myoglobinε, S-galactosidase, penicillinase and bacterial toxoids, as well as synthetic molecules such as multi-poly-DL-alanyl-poly-L-lysine and poly-L- lysine. Rabbits are immunized with the peptide-KLH conjugate to raise polyclonal antibodies. After different periods of time, serum is collected from the rabbits. The IgG fraction of the serum is then purified using a protein A Sepharose column (Pharmacia LKB, Uppsala, Sweden) to obtain the antibody which is designated anti-KDR.PS23. A sample of the expressed KDR protein is subjected to SDS-PAGE using a 7% acrylamide gel under standard conditions. The protein band is then transferred on to nitrocellulose paper for Western blot analysis and the anti-K_DIt.PS23 antibody is added at a dilution of 1:1,000 to allow the antibody to react with the protein present. A second antibody, goat anti-rabbit antibody to rabbit IgG, which binds to anti-KDR.PS23, is then added. The detection of proteins which react with the antibodies is performed by autoradiography of bands using an ECL system (Amersham, Chicago, IL) . The results are depicted in Figure 12. Figure 12 shows that a 190 kD protein is present in the cells transfected with the vector containing the KDR gene, but is absent in cells transfected with vector alone. The size of this protein is consistent with it being encoded by the KDR gene, in that the predicted amino acid sequence for the unglycosylated KDR protein is 156 kD, and that sequence contains 18 putative ertracellular glycosylation sites which would account for the balance of the size seen in the 190 kD band. The expressed receptor is then used to identify the growth factor which interacts with the receptor. In order to test the hypothesis that the KDR protein is a receptor for VEGF, radioligand binding studies are performed. VEGF (provided by D. Gospodarowicz) is radiolabelled with 125I. Cells are transfected with either the vector pcDNAltkpASP alone (bars 1 and 2 of Figure 13) or with the vector containing the KDR gene (bars 3 and 4) . Forty-eight hours later, the transfected cell samples are washed with PBS and then incubated for 90 minutes with serum-free media containing 50 pM [ 125I]VEGF (specific activity equal to 4,000 σpm per fmol) . Excess nonradioactive VEGF, 5 nM, is added to some samples (bars 2 and 4) to define specific binding sites. The samples are washed with ice cold PBS, and the cells are transferred to gamma-counting tubes using a detergent, 0.1% lubrol. The results of the radioligand binding studies are depicted in Figure 13. Figure 13 shows that CMT-3 cells transfected with vector containing the KDR gene contain specific binding sites for [ I]VEGF (compare bars 3 and 4) , while cells transfected with vector alone do not (compare bars 1 and 2) . Further evidence that the KDR gene encodes a receptor for VEGF is demonstrated by affinity cross-linking studies (Figure 14) . Figure 14 depicts the results of affinity cross-linking of [ 125 I]VEGF to CMT-3 cells which express the KDR protein. CMT-3 cells are transfected with either the pcDNAltkpASP vector alone (lane 1 of Figure 14) or with the vector containing the KDR gene (lane 2) . Forty-eight hours later, the cells are washed in PBS, and serum free media containing 200 pM [ 125 I]VEGF is added. After 90 minutes at room temperature, an affinity cross-linker disuccinimidyl suberate (Pierce Biochemicals, Rockford, IL) , 0.5mM, is added for 15 minutes. The samples are then subjected to SDS-PAGE autoradiography. Three protein bands are seen in SDS-PAGE autoradiograms from samples of CMT-3 cells transfected with the KDR gene and cross-linked to [ 125I]VEGF (lane 1) . The size of band 1 (235 kD) is consistent with it being the 190 kD protein seen by Western blot analysis (Figure 12) , because a 45 kD [ 125 I] VEGF dimer plus 190 kD would migrate in a manner identical to band 1. The origin of band 2 is not clear, but may represent an altered glycosylation form of band 1. Band 3 (22.5 kD) is most likely VEGF itself, and can be seen faintly in cells transfected with vector alone (lane 2) . The novel KDR gene of this invention is significant for several reasons. Studies of the cellular mechanisms by which receptors function in signal transduction have led in the past to a better understanding of how cells grow in both normal and diseased states. Receptor tyrosine kinases, in particular, have received a great deal of attention because of the observation that a number of RTK are the cellular counterparts for viral oncogenes, implying a direct correlation between changes in the expression of RTK and cancer. In view of this, it is likely that pharmaceuticals targeted at RTK will inhibit the changes in cell growth associated with cancer. In additon, it is likely that monitoring the levels of expression of RTK will prove valuable in diagnosing the onset of cancer. The described cDNA is isolated from a human endothelial cell library. Endothelial cells participate in angiogenesis, the formation of new blood capillaries. Previous work directed towards identifying the growth factors which regulate angiogenesis have primarily focused upon FGF (13), although recent evidence has indicated that other growth factors may be involved as well (12,15,29). This evidence consists of the observations that: 1) FGF does not contain a signal sequence (24) and thus may not be secreted from cells in a manner consistent with the tight regulation of angiogenesis, and 2) endothelial cells synthesize FGF and yet are normally resting (15) . Our discovery, then, of a novel growth factor receptor may ultimately clarify these inconsistencies and lead to a better understanding of endothelial cell function. The teachings of this invention can be readily used by those skilled the art for the purpose of testing pharmaceuticals targeted at the KDR protein. Two examples of approaches which can be used for this purpose are now given. First, the methods described in this invention for studying the interaction of VEGF with KDR protein can be used to test for pharmaceuticals which will antagonize that interaction. For these studies, cells expressing the KDR protein are incubated with [125I]VEGF, together with a candidate pharmaceutical. Inhibition of radioligand binding is tested for; significant inhibition indicates the candidate is an antagonist. Permanent expression of the KDR protein in a cell type such as NIH3T3 cells would make these studies less laborious. This can be easily achieved by those skilled in the art using the described methods. Second, using the teachings of this invention, those skilled in the art can study structural properties of the KDR protein involved in receptor function. This structural information can then be used to more rationally design pharmaceuticals which inhibit that function. Mutagenesis of the KDR gene by well established protocols is one approach, crystallization of the receptor binding site is another. Bibliography 1. Yarden Y., and A. Ullrich, Ann. Rev. Biochem.. 57, 433-478 (1988). 2. Bargmann, C, et al.. Nature. 319. 226-230 (1986). 3. Yarden, Y., et al., EMBO J.. 6 , 3341-3351 (1987) . 4. Coussens, L. , et al.. Nature, 320. 277-280 (1986) . 5. Slamon, D., et al.. Science. 244. 707-712 (1989) . 6. Ullrich, A. and Schlessinger, J. , Cell. 61, 203-212 (1990) . 7. Ruta, M. , et al., Oncogene, 3., 9-15 (1988) . 8. Strathmann, M. , et al., Proc. Natl. Acad. Sci.. 86. 8698-8702 (1989) . 9. Streuli, M. , et al., Proc. Natl. Acad. Sci.. 86 / 8698-8702 (1989) . 10. Wilkes, A.F., Proc. Natl. Acad. Sci.. 86. 1603-1607 (1989) . 11. Folkman, J. , and Klagsbrun, M. , Science. 235. 442-445 (1987) . 12. Ishikawa, F., et al.. Nature. 338. 557-562 (1989). 13. Baird, A., and Bohlen, P., in Peptide Growth Factors and Their Receptors, pages 369-418 (Spron, M.B., and Roberts, A.B., eds. 1990). 14. Senger, D.R. , et al.. Science. 219. 983-985 (1983) . 15. Gospodarowicz, D. , et al., Proc. Natl. Acad. Sci.. 86. 7311-7315 (1989) . 16. Leung, D.W. , et al.. Science. 246 f 1306-1309 (1989) . 17. Maglione, D. , et al., Proc. Natl. Acad. Sci.. 88, 9267-9271 (1991). 18. Gronwald, R. , et al., Proc. Natl. Acad. Sci.. 85. 3435-3439 (1988) . 19. Shows, T. , et al. , Somat. Del. Mol. Gen.. 10, 315-318 (1984). 20. Rainer, G., et al., Proc. Natl. Acad. Sci.. 85. 3435-3439 (1988) . 21. Lee, P. L. , et al.. Science, 245. 57-60 (1989) . 22. Sanger, F., et al., Proc. Natl. Acad. Sci.. 74. 5463-5467 (1977) . 23. Folkman, J. , Cancer Res. , 46. 467-473 (1986) . 24. Burgess, W. and Maciag, T. , Ann. Rev. Biochem.. 58. 575-606 (1989) . 25. Matthews, W., et al., Proc. Natl. Acad. Sci.. 88. 9026-9030 (1991). 26. Hannink, M. and Donoghue, D., Proc. Natl. Acad. Sci.. 82, 7894-7898 (1985) . 27. Sambrook, J. , et al.. Molecule Cloning: A Laboratory Manual. 2nd ed. , Cold Spring Harbor Lciboratory Press, Cold Spring Harbor, N.Y. (1989) . 28. Matsui, T., et al., Science. 243, 800-804 (1989) . 29. Conn, G. , et al., Proc. Natl. Acad. Sci. , 87. 2628-2632 (1990) . SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: Terman, Bruce I Carrion, Miguel E (ii) TITLE OF INVENTION: Identification of a Novel Human Growth Factor Receptor (iii) NUMBER OF SEQUENCES: 14 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Alan M. Gordon American Cyanamid Company (B) STREET: 1937 West Main Street, P.O. Box 60 (C) CITY: Stamford (D) STATE: Connecticut (E) COUNTRY: USA (F) ZIP: 06904 (v) COMPUTER READAB.LE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC AT (C) OPERATING SYSTEM: MS-DOS - 34 - (D) SOFTWARE: ASCII from IBM DW 4 (Vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: (C) CLASSIFICATION: 10 (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: 07/657,236 15 (B) FILING DATE: February 22, 1991 (viii) ATTO.RNEY/AGENT INFORMATION: (A) NAME: Gordon, Alan M. 20 (B) REGISTRATION NUMBER: 30,637 (C) REFERENCE/DOCKET NUMBER: 31,298-01 25 (ix) TE.LECO.MMUNICATION INFORMATION: (A) TELEPHONE: 203 321 2719 (B) TELEFAX: 203 321 2971 30 (C) TELEX: (2) INFORMATION FOR SEQ ID NO: 1: 35 (i) SEQUENCE CHARACTERISTICS: - 35 - (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESSS: single (D) TOPOLOGY: linear (ϋ) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1: GTCGAC AAY CTG TTG GGR GCC TGC AAC 27 (2) INFORMATION FOR SEQ ID NO: 2 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 35 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESSS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2: GAATTC AG CAC KTT NCT RGC YGC CAG GTC TGY GTC 35 (2) INFO.RMATION FOR SEQ ID NO: 3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 363 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESSS: single (D) TOPOLOGY: linear (ii) MOLECU.LE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3: GAA TTC TGC AAA TTT GGA AAC CTG TCC ACT TAC CTG 36 AGG ACG AAG AGA AAT GAA TTT GTC CCC TAC AAG ACC 72 AAA GGG GCA CGA TTC CGT CAA GGG AAA GAC TAC GTT 108 GGA GCA ATC CCT GTG GAT CTG AAA CGG CGC TTG GAC 144 ACG CAT CAC CAG TAG CCA GAG CTC AGC CAG CTC TGG 180 ATT TGT GGA GGA GAA GTC CCT CAG TGA TGT AGA AGA 216 AGA GGA AGC TCC TGA AGA TCT GTA TAA GGA CTT CCT 252 GAC CTT GGA GCA TCT CAT CTG TTA CAG TTT CCA AGT 288 GGC TAA GGG CAT GGA GTT CTT GGC ATC GCG AAA GTG 324 TAT CCA CAG AGA CCT GGC AGC CAG GAA CGT GCT GAA 360 - 37 - TTC 363 (2) INFORMATION FOR SEQ ID NO: 4 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 251 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESSS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) ( i) SEQUENCE DESCRIPTION: SEQ ID NO: 4: GTC GAC AAT CTG TTG GGG GCC TGC ACC ATC CCA ACA 36 TCC TGC TGC TCT ACA ACT ATT TTT ATG ACC GGA GGA 72 GGA TCT ACT TGA TTC TAG AGT ATG CCC CCC GCG GAG 108 CTC TAC AAG GAG CTG CAG AAG AGC TGC ACA TTT GAC 144 GAG CAG CGA ACA GCC ACG ATC ATG GAG GAG TTG GCA 180 GAT GCT CTA ATG TAC TGC CGT GGG AAG AAG GTG ATT 216 CAC AGA GAC CTG GCA GCC AGC AAC GTG CTG AAT TC 251 (2) INFORMATION FOR SEQ ID NO: 5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 510 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESSS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: PDGF Receptor DNA (B) LOCATION: Internal sequence (x) PUBLICATION INFORMATION: (A) AUTHORS: Gronwald, R. , et al. (B) JOURNAL: Proc. Natl. Acad. Sci. (C) VOLUME: 85 (D) PAGES: 3435-3439 (E) DATE: 1988 ( i) SEQUENCE DESCRIPTION: SEQ ID NO: 5: AAC CTG TGG GGG CCT GCA CCA AAG GAG GAC CAT CTA 36 TAT CAT CTA TAT CAT CAC TGA GTA CTG CCG CTA CGG 72 AGA CCT GGT GGA CTA CCT GCA CCG CAA CAA ACA CAC 108 CTT CCT GCA GCA CCA CTC CGA CAA GCG CCG CCC GCC 144 CAG CGC GGA GCT CTA CAG CAA TGC TCT GCC CGT TGG 180 GCT CCC CCT GCC CAG CCA TGT GTC CTT GAC CGG GGG 216 AGA GCG ACG GTG GCT ACA TGG ACA TGA GCA AGG ACG 252 AGT CGG TGG ACT ATG TGC CCA TGC TGG ACA TGA AAG 288 GAG ACG TCA AAT AGC AGA CAT CGA GTC CTC CAA CTA 324 CAT GGC CCC TTA CGA TAA CTA CGT TCC CTC TGC CCC 360 TGA GAG GAC CTG CCG AGC AAC TTT GAT CAA CGA GTC 396 TCC AGT GCT AAG CTA CAT GGA CCT CGT GGG CTT CAG 432 CTA CCA GGT GGC CAA TGG CAT GGA GTT CTG GCC TCC 468 AAG AAC TGC GTC CAC AGA GAC CTG GCG GCT AGG AAC 504 GTC CTT 510 (2) INFORMATION FOR SEQ ID NO: 6: (i) SEQUENCE CHARACTERISTICS: (A) .LENGTH: 255 base pairs (B) TYPE: nucleic acid (C) ST.RANDEDNESSS: single 5 (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: 10 (A) NAME/KEY: FGF Receptor DNA (B) LOCATION: Internal sequence 15 (x) PUBLICATION INFORMATION: (A) AUTHORS: Ruta, M. , et al. (B) JOURNAL: Onσogene 20 (C) VOLUME: 3 (D) PAGES: 9-15 25 (E) DATE: 1988 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6: AAC CTG CTG GGG GCC TGC ACG CAG GAT GGT CCC TTG 36 30 TAT GTC ATC GTG GAG TAT GCC TCC AAG GGC AAC CTG 72 CGG GAG TAC CTG CAG ACC CGG AGG CCC CCA GGG CTG 108 35 GA TAC TGC TAT AAC CCC AGC CAC AAC CCA GAG GAG 144 CAG CTC TCC TCC .AAG GAC CTG GTG TCC TGC GCC TAC 180 CAG GAG GCC CGA GGC ATG GAG TAT CTG GCC TCC AAG 216 AAG TGC ATA CAC CGA GAC CTG GCA GCC AGG AAT GTC 252 CTG 255 (2) INFORMATION FOR SEQ ID NO: 7: (i) SEQUENCE CHARACTERISTICS: (A) .LENGTH: 4236 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) ( i) SEQUENCE DESCRIPTION: SEQ ID NO: 7: ATG GAG AGC AAG GTG CTG CTG GCC GTC GCC CTG 33 Met Glu Ser Lys Val Leu Leu Ala Val Ala Leu 1 5 10 TGG CTC TGC GTG GAG ACC CGG GCC GCC TCT GTG GGT 69 Trp Leu Cys Val Glu Thr Arg Ala Ala Ser Val Gly 15 20 TTG CCT AGT GTT TCT CTT GAT CTG CCC AGG CTC AGC 105 Leu Pro Ser Val Ser Leu Asp Leu Pro Arg Leu Ser 25 30 35 ATA CAA AAA GAC ATA CTT ACA ATT AAG GCT AAT ACA 141 lie Gin Lys Asp lie Leu Thr lie Lys Ala Asn Thr 40 45 ACT CTT CAA ATT ACT TGC AGG GGA CAG AGG GAC TTG 177 Thr Leu Gin lie Thr Cys Arg Gly Gin Arg Asp Leu 50 55 GAC TGG CTT TGG CCC AAT AAT CAG AGT GGC AGT GAG 213 Asp Trp Leu Trp Pro Asn Asn Gin Ser Gly Ser Glu 60 65 70 CAA AGG GTG GAG GTG ACT GAG TGC AGC GAT GGC CTC 249 Gin Arg Val Glu Val Thr Glu Cys Ser Asp Gly Leu 75 80 TTC TGT AAG ACA CTC ACA ATT CCA AAA GTG ATC GGA 285 Phe Cys Lys Thr Leu Thr lie Pro Lys Val lie Gly 85 90 95 AAT GAC ACT GGA GCC TAC AAG TGC TTC TAC CGG GAA 321 Asn Asp Thr Gly Ala Tyr Lys Cys Phe Tyr Arg Glu 100 105 ACT GAC TTG GCC TCG GTC ATT TAT GTC TAT GTT CAA 357 Thr Asp Leu Ala Ser Val lie Tyr Val Tyr Val Gin 110 115 GAT TAC AGA TCT CCA TTT ATT GCT TCT GTT AGT GAC 393 Asp Tyr Arg Ser Pro Phe lie Ala Ser Val Ser Asp 120 125 130 CAA CAT GGA GTC GTG TAC ATT ACT GAG AAC AAA AAC 429 Gin His Gly Val Val Tyr lie Thr Glu Asn Lys Asn 135 140 AAA ACT GTG GTG ATT CCA TGT CTC GGG TCC ATT TCA 465 Lys Thr Val Val lie Pro Cys Leu Gly Ser lie Ser 145 150 155 AAT CTC AAC GTG TCA CTT TGT GCA AGA TAC CCA GAA 501 Asn Leu Asn Val Ser Leu Cys Ala Arg Tyr Pro Glu 160 165 AAG AGA TTT GTT CCT GAT GGT AAC AGA ATT TCC TGG 537 Lys Arg Phe Val Pro Asp Gly Asn Arg lie Ser Trp 170 175 GAC AGC AAG AAG GGC TTT ACT ATT CCC AGC TAC ATG 573 Asp Ser Lys Lys Gly Phe Thr lie Pro Ser Tyr Met 180 185 190 ATC AGC TAT GCT GGC ATG GTC TTC TGT GAA GCA AAA 609 lie Ser Tyr Ala Gly Met Val Phe Cys Glu Ala Lys 195 200 ATT AAT GAT GAA AGT TAC CAG TCT ATT ATG TAC ATA 645 lie Asn Asp Glu Ser Tyr Gin Ser lie Met Tyr lie 205 210 215 GTT GTC GTT GTA GGG TAT AGG ATT TAT GAT GTG GTT 681 Val Val Val Val Gly Tyr Arg He Tyr Asp Val Val 220 225 CTG AGT CCG TCT CAT GGA ATT GAA CTA TCT GTT GGA 717 Leu Ser Pro Ser His Gly He Glu Leu Ser Val Gly 230 235 GAA .AAG CTT GTC TTA AAT TGT ACA GCA AGA ACT GAA 753 Glu Lys Leu Val Leu Asn Cys Thr Ala Arg Thr Glu 240 245 250 CTA AAT GTG GGG ATT GAC TTC AAC TGG GAA TAC CCT 789 Leu Asn Val Gly He Asp Phe Asn Trp Glu Tyr Pro 255 260 TCT TCG AAG CAT CAG CAT AAG AAA CTT GTA AAC CGA 825 Ser Ser Lys His Gin His Lys Lys Leu Val Asn Arg 265 270 275 GAC CTA AAA ACC CAG TCT GGG AGT GAG ATG AAG AAA 861 Asp Leu Lys Thr Gin Ser Gly Ser Glu Met Lys Lys 280 285 TTT TTG AGC ACC TTA ACT ATA GAT GGT GTA ACC CGG 897 Phe Leu Ser Thr Leu Thr He Asp Gly Val Thr Arg 290 295 AGT GAC CAA GGA TTG TAC ACC TGT GCA GCA TCC AGT 933 Ser Asp Gin Gly Leu Tyr Thr Cys Ala Ala Ser Ser 300 305 310 GGG CTG ATG ACC AAG AAG AAC AGC ACA TTT GTC AGG 969 Gly Leu Met Thr Lys Lys Asn Ser Thr Phe Val Arg 315 320 GTC CAT GAA AAA CCT TTT GTT GCT TTT GGA AGT GGC 1005 Val His Glu Lys Pro Phe Val Ala Phe Gly Ser Gly 325 330 335 ATG GAA TCT CTG GTG GAA GCC ACG GTG GGG GAG CGT 1041 Met Glu Ser Leu Val Glu Ala Thr Val Gly Glu Arg 340 345 GTC AGA ATC CCT GCG AAG TAC CTT GGT TAC CCA CCC 1077 Val Arg He Pro Ala Lys Tyr Leu Gly Tyr Pro Pro 350 355 CCA GAA ATA AAA TGG TAT AAA AAT GGA ATA CCC CTT 1113 Pro Glu He Lys Trp Tyr Lys Asn Gly He Pro Leu 360 365 370 GAG TCC AAT CAC ACA ATT AAA GCG GGG CAT GTA CTG 1149 Glu Ser Asn His Thr He Lys Ala Gly His Val Leu 375 380 ACG ATT ATG GAA GTG AGT GAA AGA GAC ACA GGA AAT 1185 Thr He Met Glu Val Ser Glu Arg Asp Thr Gly Asn 385 390 395 TAC ACT GTC ATC CTT ACC AAT CCC ATT TCA AAG GAG 1221 Tyr Thr Val He Leu Thr Asn Pro He Ser Lys Glu 400 405 AAG CAG AGC CAT GTG GTC TCT CTG GTT GTG TAT GTC 1257 Lys Gin Ser His Val Val Ser Leu Val Val Tyr Val 410 415 CCA CCC CAG ATT GGT GAG AAA TCT CTA ATC TCT CCT 1293 Pro Pro Gin He Gly Glu Lys Ser Leu He Ser Pro 420 425 430 GTG GAT TCC TAC CAG TAC GGC ACC ACT CAA ACG CTG 1329 Val Asp Ser Tyr Gin Tyr Gly Thr Thr Gin Thr Leu 435 440 ACA TGT ACG GTC TAT GCC ATT CCT CCC CCG CAT CAC 1365 Thr Cys Thr Val Tyr Ala He Pro Pro Pro . His His 445 450 455 ATC CAC TGG TAT TGG CAG TTG GAG GAA GAG TGC GCC 1401 He His Trp Tyr Trp Gin Leu Glu Glu Glu Cys Ala 460 465 AAC GAG CCC AGC CAA GCT GTC TCA GTG ACA AAC CCA 1437 Asn Glu Pro Ser Gin Ala Val Ser Val Thr Asn Pro 470 475 TAC CCT TGT GAA GAA TGG AGA AGT GTG GAG GAC TTC 1473 Tyr Pro Cys Glu Glu Trp Arg Ser Val Glu Asp Phe 480 485 490 CAG GGA GGA AAT AAA ATT GAA GTT AAT AAA AAT CAA 1509 Gin Gly Gly Asn Lys He Glu Val Asn Lys Asn Gin 495 500 TTT GCT CTA ATT GAA GGA AAA AAC AAA ACT GTA AGT 1545 Phe Ala Leu He Glu Gly Lys Asn Lys Thr Val Ser 505 510 515 ACC CTT GTT ATC CAA GCG GCA AAT GTG TCA GCT TTG 1581 Thr Leu Val He Gin Ala Ala Asn Val Ser Ala Leu 520 525 TAC AAA TGT GAA GCG GTC AAC AAA GTC GGG AGA GGA 1617 Tyr Lys Cys Glu Ala Val Asn Lys Val Gly Arg Gly 530 535 GAG AGG GTG ATC TCC TTC CAC GTG ACC AGG GGT CCT 1653 Glu Arg Val He Ser Phe His Val Thr Arg Gly Pro 540 545 550 GAA ATT ACT TTG CAA CCT GAC ATG CAG CCC ACT GAG 1689 Glu He Thr Leu Gin Pro Asp Met Gin Pro Thr Glu 555 560 CAG GAG AGC GTG TCT TTG TGG TGC ACT GCA GAC AGA 1725 Gin Glu Ser Val Ser Leu Trp Cys Thr Ala Asp Arg 565 570 575 TCT ACG TTT GAG AAC CTC ACA TGG TAC AAG CTT GGC 1761 Ser Thr Phe Glu Asn Leu Thr Trp Tyr Lys Leu Gly 580 585 CCA CAG CCT CTG CCA ATC CAT GTG GGA GAG TTG CCC 1797 Pro Gin Pro Leu Pro He His Val Gly Glu Leu Pro 590 595 ACA CCT GTT TGC AAG AAC TTG GAT ACT CTT TGG AAA 1833 Thr Pro Val Cys Lys Asn Leu Asp Thr Leu Trp Lys 600 605 610 TTG AAT GCC ACC ATG TTC TCT AAT AGC ACA AAT GAC 1869 Leu Asn Ala Thr Met Phe Ser Asn Ser Thr Asn Asp 615 620 ATT TTG ATC ATG GAG CTT AAG AAT GCA TCC TTG CAG 1905 He Leu He Met Glu Leu Lys Asn Ala Ser Leu Gin 625 630 635 GAC CAA GGA GAC TAT GTC TGC CTT GCT CAA GAC AGG 1941 Asp Gin Gly Asp Tyr Val Cys Leu Ala Gin Asp Arg 640 645 AAG ACC AAG AAA AGA CAT TGC GTG GTC AGG CAG CTC 1977 Lys Thr Lys Lys Arg His Cys Val Val Arg Gin Leu 650 655 ACA GTC CTA GAG CGT GTG GCA CCC ACG ATC ACA GGA 2013 Thr Val Leu Glu Arg Val Ala Pro Thr He Thr Gly 660 665 670 AAC CTG GAG AAT CAG ACG ACA AGT ATT GGG GAA AGC 2049 Asn Leu Glu Asn Gin Thr Thr Ser He Gly Glu Ser 675 680 ATC GAA GTC TCA TGC ACG GCA TCT GGG AAT CCC CCT 2085 He Glu Val Ser Cys Thr Ala Ser Gly Asn Pro Pro 685 690 695 CCA CAG ATC ATG TGG TTT AAA GAT AAT GAG ACC CTT 2121 Pro Gin He Met Trp Phe Lys Asp Asn Glu Thr Leu 700 705 GTA GAA GAC TCA GGC ATT GTA TTG AAG GAT GGG AAC 2157 Val Glu Asp Ser Gly He Val Leu Lys Asp Gly Asn 710 715 CGG AAC CTC ACT ATC CGC AGA GTG AGG AAG GAG GAC 2193 Arg Asn .Leu Thr He Arg Arg Val Arg Lys Glu Asp 720 725 730 GAA GGC CTC TAC ACC TGC CAG GCA TGC AGT GTT CTT 2229 Glu Gly Leu Tyr Thr Cys Gin Ala Cys Ser Val Leu 735 740 GGC TGT GCA AAA GTG GAG GCA TTT TTC ATA ATA GAA 2265 Gly Cys Ala Lys Val Glu Ala Phe Phe He He Glu 745 750 755 GGT GCC CAG GAA AAG ACG AAC TTG GAA ATC ATT ATT 2301 Gly Ala Gin Glu Lys Thr Asn Leu Glu He He He 760 765 CTA GTA GGC ACG ACG GTG ATT GCC ATG TTC TTC TGG 2337 Leu Val Gly Thr Thr Val He Ala Met Phe Phe Trp 770 775 CTA CTT CTT GTC ATC ATC CTA GGG ACC GTT AAG CGG 2373 Leu Leu Leu Val He He Leu Gly Thr Val Lys Arg 780 785 790 - 49 - GCC AAT GGA GGG GAA CTG AAG ACA GGC TAC TTG TCC 2 09 Ala Asn Gly Gly Glu Leu Lys Thr Gly Tyr Leu Ser 795 800 ATC GTC ATG GAT CCA GAT GAA CTC CCA TTG GAT GAA 2445 He Val Met Asp Pro Asp Glu Leu Pro Leu Asp Glu 805 810 815 CAT TGT GAA CGA CTG CCT TAT GAT GCC AGC AAA TGG 2481 His Cys Glu Arg Leu Pro Tyr Asp Ala Ser Lys Trp 820 825 GAA TTC CCC AGA GAC CGG CTG AAC CTA GGT AAG CCT 2517 Glu Phe Pro Arg Asp Arg Leu Asn Leu Gly Lys Pro 830 835 CTT GGC CGT GGT GCC TTT GGC CAA GAG ATT GAA GCA 2553 Leu Gly Arg Gly Ala Phe Gly Gin Glu He Glu Ala 840 845 850 GAT GCC TTT GGA ATT GAC AAG ACA GCA ACT TGC AGG 2589 Asp Ala Phe Gly He Asp Lys Thr Ala Thr Cys Arg 855 860 ACA GTA GCA GTC AAA ATG TTG AAA GAA GGA GCA ACA 2625 Thr Val Ala Val Lys Met Leu Lys Glu Gly Ala Thr 865 870 875 CAC AGT GAG CAT CGA GCT CTC ATG TCT GAA CTC AAG 2661 His Ser Glu His Arg Ala Leu Met Ser Glu Leu Lys 880 885 ATC CTC ATT CAT ATT GGT CAC CAT CTC AAT GTG GTC 2697 He Leu He His He Gly His His Leu Asn Val Val 890 895 AAC CTT CTA GGT GCC TGT ACC AAG CCA GGA GGG CCA 2733 Asn Leu Leu Gly Ala Cys Thr Lys Pro Gly Gly Pro 900 905 910 CTC ATG GTG ATT GTG GAA TTC TGC AAA TTT GGA AAC 2769 Leu Met Val He Val Glu Phe Cys Lys Phe Gly Asn 915 920 CTG TCC ACT TAC CTG AGG AGC AAG AGA AAT GAA TTT 2805 Leu Ser Thr Tyr Leu Arg Ser Lys Arg Asn Glu Phe 925 930 935 GTC CCC TAC AAG ACC AAA GGG GCA CGA TTC CGT CAA 2841 Val Pro Tyr Lys Thr Lys Gly Ala Arg Phe Arg Gin 940 945 GGG AAA GAC TAC GTT GGA GCA ATC CCT GTG GAT CTG 2877 Gly Lys Asp Tyr Val Gly Ala He Pro Val Asp Leu 950 955 AAA CGG CGC TTG GAC AGC ATC ACC AGT AGC CAG AGC 2913 Lys Arg Arg Leu Asp Ser He Thr Ser Ser Gin Ser 960 965 970 TCA GCC AGC TCT GGA TTT GTG GAG GAG AAG TCC CTC 2949 Ser Ala Ser Ser Gly Phe Val Glu Glu Lys Ser Leu 975 980 AGT GAT GTA GAA GAA GAG GAA GCT CCT GAA GAT CTG 2985 ser Asp Val Glu Glu Glu Glu Ala Pro Glu Asp Leu 985 990 995 TAT AAG GAC TTC CTG ACC TTG GAG CAT CTC ATC TGT 3021 Tyr Lys Asp Phe Leu Thr Leu Glu His Leu He Cys 1000 1005 TAC AGC TTC CAA GTG GCT AAG GGC ATG GAG TTC TTG 3057 Tyr Ser Phe Gin Val Ala Lys Gly Met Glu Phe Leu 1010 1015 GCA TCG CGA AAG TGT ATC CAC AGG GAC CTG GCG GCA 3093 Ala Ser Arg Lys Cys He His Arg Asp Leu Ala Ala 1020 1025 1030 CGA AAT ATC CTC TTA TCG GAG AAG AAC GTG GTT AAA 3129 Arg Asn He Leu Leu Ser Glu Lys Asn Val Val Lys 1035 1040 ATC TGT GAC TTT GGC TTG GCC CGG GAT ATT TAT AAA 3165 He Cys Asp Phe Gly Leu Ala Arg Asp He Tyr Lys 1045 1050 1055 GAT CCA GAT TAT GTC AGA AAA GGA GAT GCT CGC CTC 3201 Asp Pro Asp Tyr Val Arg Lys Gly Asp Ala Arg Leu 1060 1065 CCT TTG AAA TGG ATG GCC CCA GAA ACA ATT TTT GAC 3237 Pro Leu Lys Trp Met Ala Pro Glu Thr He Phe Asp 1070 1075 AGA GTG TAC ACA ATC CAG AGT GAC GTC TGG TCT TTT 3273 Arg Val Tyr Thr He Gin Ser Asp Val Trp Ser Phe 1080 1085 1090 GGT GTT TTG CTG TGG GAA ATA TTT TCC TTA GGT GCT 3309 Gly Val Leu Leu Trp Glu He Phe Ser Leu Gly Ala 1095 1100 TCT CCA TAT CCT GGG GTA AAG ATT GAT GAA GAA TTT 3345 Ser Pro Tyr Pro Gly Val Lys He Asp Glu Glu Phe 1105 1110 1115 TGT AGG CGA TTG AAA GAA GGA ACT AGA ATG AGG GCC 3381 Cys Arg Arg Leu Lys Glu Gly Thr Arg Met Arg Ala 1120 1125 CCT GAT TAT ACT ACA CCA GAA ATG TAC CAG ACC ATG 3417 Pro Asp Tyr Thr Thr Pro Glu Met Tyr Gin Thr Met 1130 1135 CTG GAC TGC TGG CAC GGG GAG CCC AGT CAG AGA CCC 3453 Leu Asp Cys Trp His Gly Glu Pro Ser Gin .Arg Pro 1140 1145 1150 ACG TTT TCA GAG TTG GTG GAA CAT TTG GGA AAT CTC 3489 Thr Phe Ser Glu Leu Val Glu His Leu Gly Asn Leu 1155 1160 TTG CAA GCT AAT GCT CAG CAG GAT GGC AAA GAC TAC 3525 Leu Gin Ala Asn Ala Gin Gin Asp Gly Lys Asp Tyr 1165 1170 1175 ATT GTT CTT CCG ATA TCA GAG ACT TTG AGC ATG GAA 3561 He Val Leu Pro He Ser Glu Thr Leu Ser Met Glu 1180 1185 GAG GAT TCT GGA CTC TCT CTG CCT ACC TCA CCT GTT 3597 Glu Asp Ser Gly Leu Ser Leu Pro Thr Ser Pro Val 1190 1195 TCC TGT ATG GAG GAG GAG GAA GTA TGT GAC CCC AAA 3633 Ser Cys Met Glu Glu Glu Glu Val Cys Asp Pro Lys 1200 1205 1210 TTC CAT TAT GAC AAC ACA GCA GGA ATC AGT CAG TAT 3669 Phe His Tyr Asp Asn Thr Ala Gly He Ser Gin Tyr 1215 1220 CTG CAG AAC AGT AAG CGA AAG AGC CGG CCT GTG AGT 3705 Leu Gin Asn Ser Lys Arg Lys Ser Arg Pro Val Ser 1225 1230 1235 GTA AAA ACA TTT GAA GAT ATC CCG TTA GAA GAA CCA 3741 Val Lys Thr Phe Glu Asp He Pro Leu Glu Glu Pro 1240 1245 GAA GTA AAA GTA ATC CCA GAT GAC AAC CAG ACG GAC 3777 Glu Val Lys Val He Pro Asp Asp Asn Gin Thr Asp 1250 1255 AGT GGT ATG GTT CTT GCC TCA GAA GAG CTG AAA ACT 3813 Ser Gly Met Val Leu Ala Ser Glu Glu Leu Lys Thr 1260 1265 1270 TTG GAA GAC AGA ACC AAA TTA TCT CCA TCT TTT GGT 3849 Leu Glu Asp Arg Thr Lys Leu Ser Pro Ser Phe Gly 1275 1280 GGA ATG GTG CCC AGC AAA AGC AGG GAG TCT GTG GCA 3885 Gly Met Val Pro Ser Lys Ser Arg Glu Ser Val Ala 1285 1290 1295 TCT GAA GGC TCA AAC CAG ACA AGC GGC TAC CAG TCC 3921 Ser Glu Gly Ser Asn Gin Thr Ser Gly Tyr Gin Ser 1300 1305 GGA TAT CAC TCC GAT GAC ACA GAC ACC ACC GTG TAC 3957 Gly Tyr His Ser Asp Asp Thr Asp Thr Thr Val Tyr 1310 1315 TCC AGT GAG GAA GCA GAA CTT TTA AAG CTG ATA GAG 3993 Ser Ser Glu Glu Ala Glu Leu Leu Lys Leu He Glu 1320 1325 1330 - 54 - ATT GGA GTG CAA ACC GGT AGC ACA GCC CAG ATT CTC 4029 He Gly Val Gin Thr Gly Ser Thr Ala Gin He Leu 1335 1340 CAG CCT GAC ACG GGG ACC ACA CTG AGC TCT CCT CCT 4065 Gin Pro Asp Thr Gly Thr Thr Leu Ser Ser Pro Pro 1345 1350 1355 GTT TAAAAGGAAG CATCCACACC CCAACTCCCG GACATCACAT 4108 Val 1356 GAGAGGTCTG CTCAGATTTT GAAGTGTTGT TCTTTCCACC 4148 AGCAGGAAGT AGCCGCATTT GATTTTCATT TCGACAACAG 4188 AAAAAGGACC TCGGACTGCA GGGAGCCAGC TCTTCTAGGC 4228 TTGTGACC 4236 (2) INFORMATION FOR SEQ ID NO: 8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 433 amino acids (B) TYPE: amino acid (C) STRANDEDNESSS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE: (A) NAME/KEY: ckit proto-oncogene receptor (B) LOCATION: Amino acids 543-975 (X) PUBLICATION INFORMATION: (A) AUTHORS: Yarden, Y., et al. (B) JOURNAL: EMBO J. (C) VOLUME: 6 (D) PAGES: 3341-3351 (E) DATE: 1987 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8: Leu Thr Tyr Lys Tyr Leu Gin Lys Pro Met Tyr Glu Val Gin 543 545 550 555 Trp Lys Val Val Glu Glu He Asn Gly Asn Asn Tyr Val Tyr 560 565 570 He Asp Pro Thr Gin Leu Pro Tyr Asp His Lys Trp Glu Phe 575 580 Pro Arg Asn Arg Leu Ser Phe Gly Lys Thr Leu Gly Ala Gly 585 590 595 Ala Phe Gly Lys Val Val Ala Glu Thr Ala Tyr Gly Leu He 600 605 610 Lys Ser Asp Ala Ala Met Thr Val Ala Val Lys Met Leu Lys - 56 - 615 620 625 Pro Ser Ala His Leu Thr Glu Arg Glu Ala Leu Met Ser Glu 630 635 640 Leu Lys Val Leu Ser Tyr Leu Gly Asn His Met Asn He Val 645 650 Asn Leu Leu Gly Ala Cys Thr He Gly Gly Pro Thr Leu Val 655 660 665 He Thr Glu Tyr Cys Cys Tyr Gly Asp Leu Leu Asn Phe Leu 670 675 680 .Arg Arg Lys Arg Asp Ser Phe He Cys Ser Lys Gin Glu Asp 685 690 695 His Ala Glu Ala Ala Leu Tyr Lys Asn Leu Leu His Ser Lys 700 705 710 Glu Ser Ser Cys Ser Asp Ser Thr Asn Glu Tyr Met Asp Met 715 720 Lys Pro Gly Val Ser Tyr Val Val Pro Thr Lys Ala Asp Lys 725 730 735 Arg Arg Ser Val Arg He Gly Ser Tyr He Glu Arg Asp Val 740 745 750 Thr Pro Ala He Met Glu Asp Asp Glu Leu Ala Leu Asp Leu 755 760 765 Glu Asp Leu Leu Ser Phe Ser Tyr Gin Val Lys Gly Met Ala 770 775 780 - 57 - Phe Leu Ala Ser Lys Asn Cys He His Arg Asp Leu Ala Ala 785 790 Arg Asn He Leu Leu Thr His Gly Arg He Thr Lys He Cys 795 800 805 Asp Phe Gly Leu Ala Arg Asp He Lys Asn Asp Ser Asn Tyr 810 815 820 Val Val Lys Gly Asn Ala Arg Leu Pro Val Lys Val Met Ala 825 830 835 Pro Glu Ser He Phe Asn Cys Val Tyr Thr Glu Glu Ser Asp 840 845 850 Val Trp Ser Tyr Gly He Phe Leu Trp Glu Leu Phe Ser Leu 855 860 Gly Ser Ser Pro Tyr Pro Gly Met Pro Val Lys Ser Lys Phe 865 870 875 Tyr Lys Met He Lys Glu Gly Phe Arg Met Leu Ser Pro Glu 880 885 890 His Ala Pro Ala Glu Met Tyr Asp He Met Lys Thr Cys Trp 895 900 905 Asp Ala Asp Pro Leu Lys Arg Pro Thr Phe Lys Gin He Val 910 915 920 Gin Leu He Glu Lys Gin He Ser Glu Ser Thr Asn His He 925 930 Tyr Ser Asn Leu Ala Asn Cys Ser Pro Asn Arg Gin Lys Pro 935 940 945 Val Val Asp His Ser Val Arg He Asn Ser Val Gly Ser Thr 950 955 960 Ala Ser Ser Ser Gin Pro Leu Leu Val His Asp Asp Val 965 970 975 (2) INFORMATION FOR SEQ ID NO: 9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 437 amino acids (B) TYPE: amino acid (C) STRANDEDNESSS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE: (A) NAME/KEY: CSF-1 receptor (B) LOCATION: Amino acids 536-972 (X) PUBLICATION INFORMATION: (A) AUTHORS: Coussens, L. , et al. (B) JOURNAL: Nature (C) VOLUME: 320 (D) PAGES: 277-280 (E) DATE : 1986 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9: Leu Leu Tyr Lys Tyr Lys Gin Lys Pro Lys Tyr Gin Val Arg 536 540 545 Trp Lys He He Glu Ser Tyr Glu Gly Asn Ser Tyr Thr Phe 550 555 560 He Asp Pro Thr Gin Leu Pro Tyr Asn Glu Lys Trp Glu Phe 565 570 575 Pro Arg Asn Asn Leu Gin Phe Gly Lys Thr Leu Gly Ala Gly 580 585 590 Ala Phe Gly Lys Val Val Glu Ala Thr Ala Phe Gly Leu Gly 595 600 605 Lys Glu Asp Ala Val Leu Lys Val Ala Val Lys Met Leu Lys 610 615 ser Thr Ala His Ala Asp Glu Lys Glu Ala Leu Met Ser Glu 620 625 630 Leu Lys He Met Ser His Leu Gly Gin His Glu Asn He Val 635 640 645 Asn Leu Leu Gly Ala Cys Thr His Gly Gly Pro Val Leu Val 650 655 660 He Thr Glu Tyr Cys Cys Tyr Gly Asp Leu Leu Asn Phe Leu 665 670 675 Arg Arg Lys Ala Glu Ala Met Leu Gly Pro Ser Leu Ser Pro 680 685 Gly Gin Asp Pro Glu Gly Gly Val Asp Tyr Lys Asn He His 690 695 700 Leu Glu Lys Lys Tyr Val Arg Arg Asp Ser Gly Phe Ser Ser 705 710 715 Gin Gly Val Asp Thr Tyr Val Glu Met Arg Pro Val Ser Thr 720 725 730 Ser Ser Asn Asp Ser Phe Ser Glu Gin Asp Leu Asp Lys Glu 735 740 745 Asp Gly Arg Pro Leu Glu Leu Arg Asp Leu Leu His Phe Ser 750 755 Ser Gin Val Ala Gin Gly Met Ala Phe Leu Ala Ser Lys Asn 760 765 770 Cys He His Arg Asp Val Ala Ala Arg Asn Val Leu Leu Thr 775 780 785 Asn Gly His Val Ala Lys He Gly Asp Phe Gly Leu Ala Arg 790 795 800 Asp He Met Asn Asp Ser Asn Tyr He Val Lys Gly Asn Ala 805 810 815 Arg Leu Pro Val Lys Trp Met Ala Pro Glu Ser He Phe Asp 820 825 Cys Val Tyr Thr Val Gin Ser Asp Val Trp Ser Tyr Gly He 830 835 840 Leu Leu Trp Glu He Phe Ser Leu Gly Leu Asn Pro Tyr Pro 845 850 855 Gly He Leu Val Asn Ser Lys Phe Tyr Lys Leu Val Lys Asp 860 865 870 Gly Tyr Gin Met Ala Gin Pro Ala Phe Ala Pro Lys Asn He 875 880 885 Tyr Ser He Met Gin Ala Cys Trp Ala Leu Glu Pro Thr His 890 895 Arg Pro Thr Phe Gin Gin He Cys Ser Phe Leu Gin Glu Gin 900 905 910 Ala Gin Glu Asp Arg Arg Glu Arg Asp Tyr Thr Asn Leu Pro 915 920 925 Ser Ser Ser Arg Ser Gly Gly Ser Gly Ser Ser Ser Ser Glu 930 935 940 Leu Glu Glu Glu Ser Ser Ser Glu His Leu Thr Cys Cys Glu 945 950 955 Gin Gly Asp He Ala Gin Pro Leu Leu Gin Pro Asn Asn Tyr 960 965 in Phe Cys 970 (2) INFORMATION FOR SEQ ID NO: 10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 566 amino acids (B) TYPE: amino acid (C) STRANDEDNESSS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE: (A) NAME/KEY: PDGF receptor (B) LOCATION: Amino acids 522-1087 (x) PUBLICATION INFO.RMATION: (A) AUTHORS: Gronwald, R. , et al. (B) JOURNAL: Proc. Natl. Acad. Sci. (C) VOLUME: 85 (D) PAGES: 3435-3439 (E) DATE: 1988 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10: Met Leu Trp Gin Lys Lys Pro Arg Tyr Glu He Arg Trp Lys 522 525 530 535 Val He Glu Ser Val Ser Ser Asp Gly His Glu Tyr He Tyr 540 545 Val Asp Pro Val Gin Leu Pro Tyr Asp Ser Thr Trp Glu Leu 550 555 560 Pro Arg Asp Gin Leu Val Leu Gly Arg Thr .Leu Gly Ser Gly 565 570 575 Ala Phe Gly Gin Val Val Glu Ala Thr Ala His Gly Leu Ser 580 585 590 His Ser Gin Ala Thr Met Lys Val Ala Val Lys Met Leu Lys 595 600 605 Ser Thr Ala Arg Ser Ser Glu Lys Gin Ser Leu Met Ser Glu 610 615 Leu Lys He Met Ser His Leu Gly Pro His Leu Asn Val Val 620 625 630 Asn Leu Leu Gly Ala Cys Thr Lys Gly Gly Pro He Tyr He 635 640 645 He Thr Glu Tyr Cys Arg Tyr Gly Asp Leu Val Asp Tyr Leu 650 655 660 His Arg Asn Lys His Thr Phe Leu Gin Arg His Ser Asn Lys 665 670 675 His Cys Pro Pro Ser Ala Glu Leu Tyr Ser Asn Ala Leu Pro 680 685 Val Gly Phe Ser Leu Pro Ser His Leu Asn Leu Thr Gly Glu 690 695 700 Ser Asp Gly Gly Tyr Met Asp Met Ser Lys Asp Glu Ser He 705 710 715 Asp Tyr Val Pro Met Leu Asp Met Lys Gly Asp He Lys Tyr 720 725 730 Ala Asp He Glu Ser Pro Ser Tyr Met Ala Pro Tyr Asp Asn 735 740 745 Tyr Val Pro Ser Ala Pro Glu Arg Thr Tyr Arg Ala Thr Leu 750 755 He Asn Asp Ser Pro Val Leu Ser Tyr Thr Asp Leu Val Gly 760 765 770 Phe Ser Tyr Gin Val Ala Asn Gly Met Asp Phe Leu Ala Ser 775 780 785 Lys Asn Cys Val His Arg Asp Leu Ala Ala Arg Asn Val Leu 790 795 800 He Cys Glu Gly Lys Leu Val Lys He Cys Asp Phe Gly Phe 805 810 815 Ala Arg Asp He Met Arg Asp Ser Asn Tyr He Ser Lys Gly 820 825 Ser Thr Tyr Leu Pro Leu Lys Trp Met Ala Pro Glu Ser He 830 835 840 Phe Asn Ser Leu Tyr Thr Thr Leu Ser Asp Val Trp Ser Phe 845 850 855 Gly He Leu Leu Trp Glu He Phe Thr Leu Gly Gly Thr Pro 860 865 870 Tyr Pro Glu Leu Pro Met Asn Asp Gin Phe Tyr Asn Ala He 875 880 885 Lys Arg Gly Tyr Arg Met Ala Gin Pro Ala His Ala Ser Asp 890 895 Glu He Tyr Glu He Met Gin Lys Cys Trp Glu Glu Lys Phe 900 905 910 Glu Thr Arg Pro Pro Phe Ser Gin Leu Val Leu Leu Leu Glu 915 920 925 Arg Leu Leu Gly Glu Gly Tyr Lys Lys Lys Tyr Gin Gin Val 930 935 940 Asp Glu Glu Phe Leu Arg Ser Asp His Pro Ala He Leu Arg 945 950 955 Ser Gin Ala Arg Phe Pro Gly He His Ser Leu Arg Ser Pro 960 965 Leu Asp Thr Ser Ser Val Leu Tyr Thr Ala Val Gin Pro Asn 970 975 980 Glu Ser Asp Asn Asp Tyr He He Pro Leu Pro Asp Pro Lys 985 990 995 pro Asp Val Ala Asp Glu Gly Leu Pro Glu Gly Ser Pro Ser 1000 1005 1010 Leu Ala Ser Ser Thr Leu Asn Glu Val Asn Thr Ser Ser Thr 1015 1020 1025 He Ser Cys Asp Ser Pro Leu Glu Leu Gin Glu Glu Pro Gin 1030 1035 Gin Ala Glu Pro Glu Ala Gin Leu Glu Gin Pro Gin Asp Ser 1040 1045 1050 - 66 - Gly Cys Pro Gly Pro Leu Ala Glu Ala Glu Asp Ser Phe Leu 1055 1060 1065 Glu Gin Pro Gin Asp Ser Gly Cys Pro Gly Pro Leu Ala Glu 1070 1075 1080 Ala Glu Asp Ser Phe Leu 1085 (2) INFORMATION FOR SEQ ID NO: 11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 16 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11: TCGACGCGCG ATG GAG 16

Claims: We claim: 1. An isolated DNA sequence encoding the Kinase insert Domain containing Receptor. 2. The DNA sequence of Claim 1 wherein said sequence is a human gene. 3. An isolated DNA sequence comprising a DNA sequence capable of hybridizing with a DNA sequence encoding the amino acid sequence of Figure 7. 4. A method for the production of a growth factor receptor which comprises transforming a host cell with the DNA sequence of Claim 3 and culturing the host cell under conditions which result in expression of the gene by an expression vector. 5. The method of Claim 4 wherein the host cell is a bacteria, virus, yeast, insect or mammalian cell line. 6. The method of Claim 5 wherein the host cell is a COS-1 cell, NIH3T3 fibroblast or CMT-3 monkey kidney cell. 7. The method of Claim 5 where the expression vector is pcDNAltkpASP expression vector. 8. A lambda gtll phage harboring the clone BTIII081.8 (ATCC accession number 40,931) or the clone BTIII129.5 (ATCC Accession number 40,975). 9. A plasmid pBlueScript KS which contains the clone BTIV169 (ATCC accession number 75200) . 10. An isolated growth factor receptor designated the Kinase insert Domain containing Receptor. 11. The receptor of Claim 10 comprising the amino acid sequence of Figure 7. 12. The receptor of Claim 10 encoded by an isolated DNA sequence comprising a DNA sequence capable of hybridizing with a DNA sequence encoding the amino acid sequence of Figure 7. 13. A biologically active protein fragment which retains the receptor activity of the receptor of 5 Claim 10. 14. An isolated DNA sequence encoding a biologically active protein fragment which retains the receptor activity of an isolated growth factor receptor designated the Kinase insert Domain containing 10 Receptor. 15. An oligonucleotide primer consisting of an oligonucleotide primer having 21 bases and having a sequence depicted for Primer 1 in Figure 2. 16. An oligonucleotide primer consisting of 15 an oligonucleotide primer having 29 bases and having a sequence depicted for Primer 2 in Figure 2. 17. The 363 base pair product having the sequence depicted in Figure 4, or a biological equivalent of said sequence. 20 25 30 35

Inventors: CARRION MIGUEL EDUARDO, TERMAN BRUCE ISRAEL, CARRION, MIGUEL, EDUARDO, TERMAN, BRUCE, ISRAEL
Applicants: AMERICAN CYANAMID CO, AMERICAN CYANAMID COMPANY
Application year: 1992
Main classification: C12P21
IPC codes: C07K14, C12N1, C12N15